192 followers
Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell #lymphoma. #DLBCL https://t.co/9YODLWCemP
Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell #lymphoma. #DLBCL https://t.co/9YODLWCemP
New article: A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. https://t.co/rNj88e6mDk #DLBCL #lymsm #hematology https://t.co/eV6plc